New approach for stability study and determination of fluvoxamine in raw materials and pharmaceuticals through condensation with 2,2-dihydroxyindane-1,3-dione

Luminescence. 2020 Sep;35(6):934-940. doi: 10.1002/bio.3807. Epub 2020 Apr 21.

Abstract

The present study describes the validation of a selective spectroscopic method for assay of fluvoxamine maleate (FXM). The validated method relies on condensation of FXM with 2,2-dihydroxyindane-1,3-dione and phenylacetaldehyde using Teorell-Stenhagen buffer (pH 6.6) to give coloured fluorescent product measured at 482 nm using 386 nm as the excitation wavelength. The parameters influencing the reaction were studied precisely and adjusted accurately. The constructed calibration graph appeared rectilinear over the following range (0.8-14 μg ml-1 ) and the estimated limit of detection was 0.25 μg ml-1 . Two pharmaceutical products from the Egyptian market were assayed using the suggested method and the final results agreed with measurements from other reported methods. Moreover, the drug was subjected to diverse stress conditions including acidic, alkaline, thermal, and photolytic degradation to examine the FXM stability. Directives from the International Conference on Harmonisation guidelines were applied to establish the validity of the work.

Keywords: 2,2-dihydroxyindane-1,3-dione; fluvoxamine; pharmaceutical formulations; spectrofluorimetric; stability.

MeSH terms

  • Drug Stability
  • Egypt
  • Fluvoxamine*
  • Indans
  • Pharmaceutical Preparations*
  • Spectrometry, Fluorescence

Substances

  • 2,2-dihydroxyindane-1,3-dione
  • Indans
  • Pharmaceutical Preparations
  • Fluvoxamine